Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MJF-R6 (227-1a)] to LRRK2 (phospho T1503)
- Suitable for: WB
- Reacts with: Human
Product nameAnti-LRRK2 (phospho T1503) antibody [MJF-R6 (227-1a)]
See all LRRK2 primary antibodies
DescriptionRabbit monoclonal [MJF-R6 (227-1a)] to LRRK2 (phospho T1503)
Specificityab154423 recognizes LRRK2 only when phosphorilated at Threonine 1503.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic phosphopeptide, corresponding to residues surrounding Threonine 1503 of Human LRRK2 (UniProt: Q5S007).
- HEK293FT cells transiently transfected with wild-type LRRK2.
This antibody was developed with support of The Michael J. Fox Foundation (MJFF) with the assistance of a consortium of investigators to help accelerate LRRK2 research.
LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a multi-domain protein belonging to the ROCO family of proteins that contains a kinase and GTPase domain among its many protein interaction domains. LRRK2 is mutated in a significant number of Parkinson's disease(PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. The most common mutation replaces glycine 2019 with a serine that results in increased LRRK2 kinase activity. This indicates that inhibitors of LRRK2 kinase activity might be of therapeutic benefit for the treatment of Parkinson’s disease and has stimulated much activity in this field of research. Based upon mass spectrometry findings, a number of other residues within LRRK2 have also been found to be phosphorylated as well.
Currently, the physiological relevance of these phospho-sites is not clear. Thus with the generation of this phospho-specific antibody, it is MJFF's hope that investigators may have at hand a critical tool to assist in their research endeavors that might thereby lend further clarity to the field of LRRK2 and its role in PD pathogenesis.
Acknowledgements: The Michael J. Fox Foundation would like to acknowledge the assistance of the following laboratories and individuals, whose input, guidance and assistance in testing all phospho specific LRRK2 antibodies was critical:
• The Laboratory of Dr. Dario Alessi (University of Dundee) - Paul Davies, PhD
• The Laboratory of Dr. Mark Cookson (National Institute on Aging) - Alexandra Beilina, PhD
• The Laboratory of Dr. Johannes Gloeckner (Helmholtz Zentrum Munchen)
• The Laboratory of Dr. Takeshi Iwatsubo (University of Tokyo) - Genta Ito, PhD
• The Laboratory of Dr. Jeremy Nichols (The Parkinson's Institute)
• The Laboratory of Dr. Andrew West (University of Alabama)
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Clone numberMJF-R6 (227-1a)
Our Abpromise guarantee covers the use of ab154423 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 286 kDa.|
FunctionPositively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease.
Tissue specificityExpressed in the brain. Expressed in pyramidal neurons in all cortical laminae of the visual cortex, in neurons of the substantia nigra pars compacta and caudate putamen (at protein level). Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
Involvement in diseaseParkinson disease 8
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
Contains 12 LRR (leucine-rich) repeats.
Contains 1 protein kinase domain.
Contains 1 Roc domain.
Contains 7 WD repeats.
DomainThe seven-bladed WD repeat region is critical for synaptic vesicle trafficking and mediates interaction with multiple vesicle-associated presynaptic proteins.
The Roc domain mediates homodimerization and regulates kinase activity.
Cellular localizationMembrane. Cytoplasm. Perikaryon. Mitochondrion. Golgi apparatus. Cell projection, axon. Cell projection, dendrite. Endoplasmic reticulum. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Endosome. Lysosome. Mitochondrion outer membrane. Mitochondrion inner membrane. Mitochondrion matrix. Predominantly associated with intracytoplasmic vesicular and membranous structures (By similarity). Localized in the cytoplasm and associated with cellular membrane structures. Predominantly associated with the mitochondrial outer membrane of the mitochondria. Colocalized with RAB29 along tubular structures emerging from Golgi apparatus. Localizes in intracytoplasmic punctate structures of neuronal perikarya and dendritic and axonal processes.
- Information by UniProt
- augmented in rheumatoid arthritis 17 antibody
- AURA17 antibody
- Dardarin antibody
Lanes 1-2 : Anti-LRRK2 (phospho T1503) antibody [MJF-R6 (227-1a)] (ab154423) at 1/1000 dilution
Lanes 3-4 : Anti-LRRK2 (phospho T1503) antibody [MJF-R6 (227-1a)] (ab154423) at 1/5000 dilution
Lanes 5-6 : Monoclonal antibody against total LRRK2
Lanes 1 & 3 & 5 : HEK293FT cells, transiently transfected with wild-type Human LRRK2 immunoprecipitated for LRRK2 and subjected to an in vitro kinase assay
Lanes 2 & 4 & 6 : HEK293FT cells transiently transfected with DDDDK-tagged Human LRRK2(T1503A) immunoprecipitated for LRRK2(T1503A) and subjected to an in vitro kinase assay.
Predicted band size: 286 kDa
ab154423 has been referenced in 2 publications.
- Schmidt SH et al. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFG? motif in the kinase domain. Proc Natl Acad Sci U S A 116:14979-14988 (2019). PubMed: 31292254
- Chia R et al. Phosphorylation of LRRK2 by casein kinase 1a regulates trans-Golgi clustering via differential interaction with ARHGEF7. Nat Commun 5:5827 (2014). WB . PubMed: 25500533